Physician profile
Hal S Hemme
NPI 1194791442
$5,508.66
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,686 · 2020: $1,720 · 2021: $2,046 · 2022: $56.65.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $693.57 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $474.39 | 2019-2022 | |
| Pfizer INC. | $420.88 | 2019-2021 | |
| Amgen INC. | $390.27 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $336.62 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $333.23 | 2019-2021 | |
| Glaxosmithkline, LLC. | $318.22 | 2019-2021 | |
| Amarin Pharma, INC. | $308.36 | 2019-2021 | |
| Abbvie INC. | $290.14 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $285.44 | 2019-2021 | |
| Lilly USA, LLC | $224.45 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $202.92 | 2019-2021 | |
| Allergan, INC. | $186.07 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $178.46 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $144.73 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $130.05 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $104.38 | 2019-2021 | |
| Eisai INC. | $94.18 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $81.42 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $61.31 | 2021 | |
| Astellas Pharma US INC | $55.62 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $50.50 | 2021 | |
| Esperion Therapeutics, INC. | $38.05 | 2020 | |
| Aytu Biopharma, INC. | $29.41 | 2020 | |
| Abbott Laboratories | $23.46 | 2019 | |
| Tactile Systems Technology INC | $16.22 | 2020 | |
| Almatica Pharma LLC | $13.05 | 2021 | |
| Ibsa Pharma INC. | $11.83 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.43 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hal Hemme listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.